Venetoclax combined with olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia
Xia Li, Yile Zhou, Xiangjie Lin, Hongyan Tong, Jie Jin, Huafeng Wang · 2026
Read Venetoclax combined with olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia by Xia Li, Yile Zhou, Xiangjie Lin, Hongyan Tong, Jie Jin, Huafeng Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13661861.txt.
Description
Li and five co-authors report a first-line drug combination for a rare leukemia in this two thousand twenty-six study. Mixed-phenotype acute leukemia shows traits of two leukemia families at once, and the form carrying the Philadelphia chromosome has few good treatment options and no standard guidelines.
Five patients received venetoclax plus olverembatinib and prednisone. All five reached complete remission after the first round, with no measurable disease left. During later rounds, though, two patients developed severe drops in blood cells and died of lung infections, while the other three went on to stem cell transplants and stayed in deep remission. The authors urge careful dose tuning, since the regimen works but can hit blood counts hard.
Catalog record
| CREATOR | Xia Li, Yile Zhou, Xiangjie Lin, Hongyan Tong, Jie Jin, Huafeng Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |